GHRP-2 Spray is a research-use peptide formulation containing GHRP-2 (pralmorelin), a synthetic hexapeptide agonist of the growth hormone secretagogue receptor (GHSR). GHRP-2 is structurally related to, but molecularly distinct from, GHRP-6 — the two share a C-terminal tetrapeptide but differ at the N-terminus by roughly 55 Da — and is pharmacologically distinct from Ipamorelin in its comparative selectivity profile. Helix Bio supplies research materials for qualified laboratory and scientific applications. GHRP-2 Spray is offered strictly for research use and is not intended for human or veterinary consumption, diagnosis, treatment, or prevention of disease.
HPLC certified
Independent analysis
Highest standard
Full traceability
GHRP-2 is a synthetic hexapeptide commonly identified by the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, with the international nonproprietary name pralmorelin. Scientific literature describes it as an agonist of the growth hormone secretagogue receptor (GHSR), the receptor family also engaged by endogenous ghrelin.
GHRP-2 shares a C-terminal tetrapeptide sequence with GHRP-6 but is a molecularly distinct compound — the two differ at the N-terminal residues, and GHRP-6's extra tryptophan raises its molecular weight roughly 55 Da above GHRP-2's, a gap that functions as a practical identity check between the two on mass spectrometry. GHRP-2 also differs pharmacologically from Ipamorelin: published literature associates GHRP-2, like other early-generation GHRPs, with some ACTH/cortisol release alongside GH release, while Ipamorelin's literature emphasizes comparative selectivity for GH release specifically.
A spray format can be relevant when researchers are studying peptide formulation science, delivery-format comparison, or analytical reproducibility in controlled experimental models. "Spray" describes this product's physical presentation; it does not by itself establish an administration route, and no route-specific claim is made for this product — a distinction that matters more than usual for GHRP-2 specifically, given its current FDA 503B Category 2 listing names injectable and nasal routes directly.
For laboratory work, researchers should distinguish between the scientific literature surrounding GHRP-2 generally and the specifications of this particular commercial research material, and should confirm the salt form (hydrochloride vs. acetate) and CID against the applicable lot's documentation rather than assuming either. Experimental results depend on factors such as peptide identity, purity, formulation, experimental model, analytical method, and study design.
The existence of published research does not establish that GHRP-2 Spray is safe or effective for use in humans. GHRP-2 is not an FDA-approved drug in the United States, and remains listed on FDA's 503B Category 2 bulk drug substances list (injectable and nasal routes) as of the most recent verified check.
GHRP-2's identity carries more verification complexity than most single-compound listings — two PubChem CIDs for one structure, a salt-form split between the diagnostic and research markets, and a name close enough to GHRP-6 that mislabeling is a genuine, documented risk in this product category. A general purity claim doesn't resolve any of that.
Helix Bio states that its research peptide catalog uses independent HPLC testing for purity assessment and mass spectrometry for molecular identity confirmation. The company also states that batch-specific Certificates of Analysis are available for its products.
For GHRP-2 Spray, researchers should verify the applicable product documentation and current lot information — including salt form and molecular-weight confirmation — rather than relying solely on a general product description.
GHRP-2 Spray is intended for qualified users working in legitimate laboratory or scientific research environments, including:
The product is not intended for personal experimentation, self-administration, human consumption, veterinary use, or medical treatment.
| Specification | Details |
|---|---|
| Product Name | GHRP-2 Spray |
| Research Category | Growth Hormone Secretagogue / Research Peptide |
| Compound | GHRP-2 (Pralmorelin) |
| Chemical Class | Synthetic hexapeptide |
| Related Peptide | Structurally related to GHRP-6; pharmacologically distinct from Ipamorelin |
| Sequence | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 |
| Receptor/Target | Growth hormone secretagogue receptor (GHSR) |
| Salt Form | Not confirmed for this product — HCl and acetate forms both exist in the market |
| Format | Spray formulation |
| Intended Use | Research and laboratory investigation only |
| Human Use | Not intended for human consumption |
| Veterinary Use | Not intended for veterinary use |
| Purity | Refer to current lot-specific product documentation |
| Identity Testing | Refer to applicable Certificate of Analysis |
| Packaging | Refer to current product listing |
| Storage | Follow current product-specific documentation |
| Manufacturer | Helix Bio |
| Country of Origin | Not specified; verify current product documentation |
Reference identifiers: molecular formula C45H55N9O6, molecular weight ≈817.99 g/mol, PubChem CIDs 6918245 and 6852372 (both resolve to this structure).
GHRP-2 has a documented research history connected to GH-axis pharmacology, distinct in specific ways from both GHRP-6 and Ipamorelin.
Research on GHRP-2 has examined GHSR binding and downstream growth hormone release in cellular, animal, and some human pharmacological studies. This receptor relationship places GHRP-2 in the same broad mechanistic family as Ipamorelin and GHRP-6, but the compounds are not interchangeable in either structure or documented pharmacological selectivity.
Comparative and analytical research relevant to this compound often focuses on the structural distinction between GHRP-2 and GHRP-6 — the shared C-terminal tetrapeptide and the differing N-terminal residues — since the two names are similar enough that misidentification is a documented practical concern in this product category.
Published pharmacology associates GHRP-2 with some ACTH and cortisol release alongside GH release, in contrast to Ipamorelin's documented comparative selectivity for GH release with minimal effect on other pituitary hormones. This is a genuine mechanistic distinction relevant to experimental design, not a claim that one compound is superior to the other.
GHRP-2's unnatural D-2-Nal residue has been cited as a characterization complexity in FDA's own stated rationale for its continued 503B Category 2 bulk drug substances listing. Researchers working with GHRP-2 in a regulatory or compounding-adjacent context should treat this as current, form-specific regulatory information rather than general peptide-market commentary.
Analytical quality is important when working with research peptides because impurities, degradation products, incorrect identity, or inconsistent concentration can introduce unwanted variables into an experiment. For GHRP-2 specifically, purity testing alone does not resolve every identity question — confirming the salt form and molecular weight is a separate, necessary step given the HCl/acetate split documented across the market.
Helix Bio states that its peptide materials are subjected to independent HPLC testing for purity and mass spectrometry for molecular identity. It also states that batch-specific Certificates of Analysis are available for its products.
For a specific GHRP-2 Spray lot, researchers should consult the applicable COA and product documentation for the actual analytical results. A general catalog statement should not be treated as a substitute for lot-specific documentation.
Researchers should assess, where applicable:
No certification, regulatory approval, or quality claim should be inferred unless it is explicitly documented by the manufacturer or relevant regulatory authority.
Storage and handling requirements should be determined from the current GHRP-2 Spray product documentation and lot-specific instructions.
Storage guidance should not be inferred from protocols for GHRP-6, Ipamorelin, a lyophilized GHRP-2 preparation, or another Spray product, because formulation, salt form, and packaging can affect stability.
Helix Bio's website describes research materials as being supplied to laboratories and institutions in the United States and describes tracked shipping and cold-chain handling within its fulfillment process.
Because shipping conditions, packaging specifications, availability, and delivery requirements may change, researchers should review the current Helix Bio shipping information and product listing before ordering.
Product packaging should remain appropriately labeled and handled as research material after delivery. Researchers are responsible for following applicable institutional, federal, state, and local requirements governing research materials.
GHRP-2 Spray is sold by Helix Bio for research and laboratory purposes only. It is not intended for human or veterinary consumption, self-administration, diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition.
"Spray" describes this product's physical format and does not by itself establish an administration route. Helix Bio does not represent this product as intended for nasal, intranasal, mucosal, oral, sublingual, or any other specific route of use.
GHRP-2 is not an FDA-approved drug in the United States. As of the most recent verified check, GHRP-2 remains listed on FDA's 503B bulk drug substances Category 2 list, covering injectable and nasal routes specifically — this status should be re-verified against the current FDA list at time of publication. FDA approval status should not be inferred from published research, product availability, or laboratory use.
This product is not a dietary supplement, consumer wellness product, or medical treatment. Researchers are responsible for determining whether a material is appropriate for their intended experimental application and for complying with applicable institutional and regulatory requirements.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Amycretin is a peptide and orforglipron is not. How that chemistry explains the formulations, trial results, and approval status of both GLP-1 pills.
Five peptide sellers got FDA warning letters in September 2026. See who was named, why the research label failed, and the full 2026 enforcement timeline.
In July 2026, the FDA's advisory committee recommended 6 peptides for the 503A bulk list. None are on it yet. What the vote changed and what it didn't.
